New hope for fabry patients: Long-Term drug safety confirmed

NCT ID NCT04049760

First seen Feb 05, 2026 · Last updated Jun 13, 2026 · Updated 24 times

Summary

This study looked at the long-term safety of a drug called migalastat in 16 people over age 12 with Fabry disease, a rare genetic disorder. Participants had already completed an earlier study and continued taking migalastat to see if it was safe and how it affected kidney function. The goal was to manage the disease over time, not to cure it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Cincinnati Children's Hospital

    Cincinnati, Ohio, 45229, United States

  • Lysosomal & Rare Disorders Research & Treatment Center

    Fairfax, Virginia, 22030, United States

  • Royal Free London NHS Foundation Trust

    London, United Kingdom

  • The Emory Clinic

    Atlanta, Georgia, 30322, United States

  • University of Minnesota Masonic Children's Hospital and Clinics

    Minneapolis, Minnesota, 55454, United States

  • University of South Florida

    Tampa, Florida, 33606, United States

Conditions

Explore the condition pages connected to this study.